Walgreens Boots Alliance, Inc. (W8AD.XC)
| Previous close | 16.13 |
| Open | 16.13 |
| Bid | 0.00 x 0 |
| Ask | 16.11 x 0 |
| Day's range | 16.13 - 16.13 |
| 52-week range | 15.94 - 28.83 |
| Volume | |
| Avg. volume | 15 |
| Market cap | 14.53B |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.43 |
| Earnings date | 25 June 2024 - 01 July 2024 |
| Forward dividend & yield | 0.93 (5.80%) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | N/A |
- Reuters
Walgreens launches own brand of opioid overdose reversal drug
U.S. pharmacy chain operator Walgreens Boots Alliance said on Wednesday it has launched its own brand of popular overdose reversal drug, naloxone, which would be available over-the-counter (OTC). The launch comes weeks after Walgreens' brand was approved by the U.S. Food and Drug Administration in April. Opioid abuse has plagued the United States for more than two decades and killed more than half a million Americans, with fentanyl and synthetic versions being a major culprit in recent years, according to government data.
Business WireWalgreens Brand Naloxone Available Online and In Stores This Month
DEERFIELD, Ill., May 15, 2024--Walgreens today announced it is expanding access to an over the counter, life-saving medication with the launch of Walgreens Brand Naloxone HCI Nasal Spray.
ZacksWalgreens Boots Alliance (WBA) Outperforms Broader Market: What You Need to Know
Walgreens Boots Alliance (WBA) closed at $18.35 in the latest trading session, marking a +1.27% move from the prior day.
